Holen Sie sich die Stockscreener-App
99.36
1.43%
-1.44
Handel nachbörslich:
99.36
Schlusskurs vom Vortag:
$100.80
Offen:
$99.94
24-Stunden-Volumen:
7.40M
Relative Volume:
1.14
Marktkapitalisierung:
$146.96B
Einnahmen:
$16.75B
Nettoeinkommen (Verlust:
$1.85B
KGV:
79.49
EPS:
1.25
Netto-Cashflow:
$2.37B
1W Leistung:
-1.32%
1M Leistung:
-1.43%
6M Leistung:
+19.21%
1J Leistung:
+45.07%
1-Tages-Spanne:
$98.02
$100.42
1-Wochen-Bereich:
$98.02
$104.35
52-Wochen-Spanne:
$66.80
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Vergleichen Sie BSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
99.36 | 146.96B | 16.75B | 1.85B | 2.37B | 1.25 |
|
ABT
Abbott Laboratories
|
130.82 | 226.88B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
364.50 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.63 | 112.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
$100 Invested In Boston Scientific 5 Years Ago Would Be Worth This Much Today - Benzinga
Goldman Sachs Adjusts Price Target on Boston Scientific to $116 From $119, Maintains Buy Rating - Marketscreener.com
The Zacks Analyst Blog Highlights Tesla, The Home Depot, Boston Scientific, Frequency Electronics and Bridger Aerospace - Yahoo Finance
Top Stock Reports for Tesla, Home Depot & Boston Scientific - MSN
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic - Yahoo Finance
Boston Scientific SVP Vance Brown sells shares worth $486,702 By Investing.com - Investing.com Australia
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Market Makes A Big Shift: DoorDash, Heico, Boston Scientific In Focus - Investor's Business Daily
Boston Scientific SVP Vance Brown sells shares worth $486,702 - Investing.com India
Returns Are Gaining Momentum At Boston Scientific (NYSE:BSX) - Yahoo Finance
Boston Scientific CEO gets 14% boost in compensation - The Business Journals
November 21st Options Now Available For Boston Scientific (BSX) - Nasdaq
RBC Capital maintains Outperform on Boston Scientific shares, $116 target - Investing.com
Investors more bullish on Boston Scientific (NYSE:BSX) this week as stock grows 5.6%, despite earnings trending downwards over past five years - Yahoo Finance
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – BSX - Business Wire
Form DEF 14A BOSTON SCIENTIFIC CORP For: Mar 19 - StreetInsider.com
Medtronic, Abbott Block Boston Scientific Heart Valve IP - Law360
Is Boston Scientific Corporation (BSX) the Top Stock to Buy According to Marshall Wace LLP? - Insider Monkey
Boston Scientific (BSX) Gains As Market Dips: What You Should Know - Yahoo Finance
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Neurotech Devices Market Is Booming Worldwide 2025-2032 | - openPR
Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching - Yahoo Finance
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now? - Yahoo Finance
Boston Scientific’s SWOT analysis: medtech giant’s stock poised for growth By Investing.com - Investing.com South Africa
Boston Scientific’s SWOT analysis: medtech giant’s stock poised for growth - Investing.com
Neurosurgery Market Size to Reach USD 6.8 Billion by 2034, Growing at 4.5% CAGR with Technological Advancements and Rising Focus on Personalized Medicine – Analysis by TMR - GlobeNewswire Inc.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Boston Scientific (NYSE:BSX) Sees 4% Price Rise Following Strong Earnings Report - Yahoo Finance
Boston Scientific Gains 42.2% in a Year: What's Driving the Stock? - Yahoo Finance
Boston Scientific price target raised to $110 from $100 at Bernstein - MSN
Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX) - Yahoo Finance
Boston Scientific (BSX) Down 4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
4C raises $175M for mitral valve technology - BioWorld Online
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
How Boston Scientific (sort of) became ‘Minnesota Scientific’ - Star Tribune
Boston Scientific at TD Cowen Conference: Strategic Growth Insights - Investing.com
Boston Scientific leads $175M investment in 4C Medical - MedTech Dive
Boston Scientific (BSX) Gains But Lags Market: What You Should Know - Yahoo Finance
Ajax, Boston Sci partner to develop new heart failure treatment - BioWorld Online
Boston Scientific Stock: Is BSX Outperforming the Healthcare Sector? - Nasdaq
Insider Sell: Jeffrey Mirviss Sells 13,022 Shares of Boston Scie - GuruFocus.com
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views? - Yahoo Finance
Boston Scientific Stock: Is BSX Outperforming The Healthcare Sector? - Barchart
Five things you need to know, and going for a chilly swim - The Business Journals
Goldman Sachs Adjusts Price Target on Boston Scientific to $119 From $118, Keeps Buy Rating - Marketscreener.com
Boston Scientific buys Tivus system developer SoniVie in $540m deal - Medical Device Network
KKR (NYSE:KKR) Partners With Boston Scientific And Ajax Health In US$4B Venture To Tackle Heart Failure - Yahoo Finance
Boston Scientific Buying $600M Ultrasound System Developer - Law360
Boston Scientific to acquire Sonivie for up to $600M - BioWorld Online
Beyond The Numbers: 17 Analysts Discuss Boston Scientific Stock - Benzinga
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):